Lanreotide (Somatuline Depot)

Somatuline Depot (lanreotide) is covered for FDA‑approved indications — long‑term treatment of acromegaly (when surgery/radiation are inadequate or not an option) and for unresectable/metastatic well‑ or moderately differentiated gastroenteropancreatic neuroendocrine tumors (oncology uses handled in the Medical Oncology program); off‑label/compendial‑unsupported uses are not covered. Approval for acromegaly requires documented clinical signs, a high pretreatment age/gender‑adjusted IGF‑1, and that the patient is not a surgical candidate or had noncurative surgery (reauthorization requires decreased/normalized IGF‑1), is limited to 12 months, and requires monitoring for gallstones, blood glucose and thyroid function, review of CYP3A4 narrow‑therapeutic‑index drug interactions, and cardiac assessment as indicated.

"No off-label uses meet evidence standards*"

Sign up to see full coverage criteria, indications, and limitations.